Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis




Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab




Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.

October 2025

Pathways Modulating IMIDs: Webinar Highlights Podcast




Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.

September 2025

Author Interview: Doctor David Kellner, September 2025




Join Professor Peter Nash from Griffith University in Brisbane and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology at UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies




Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases